Cibc Asset Management Inc Bluebird Bio, Inc. Transaction History

Cibc Asset Management Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Oct 30, 2019	SELL	$59.47 - $93.1 $105,856 - $165,718	-1,780 Closed	0 $0
Q1 2019 May 06, 2019	BUY	$64.44 - $104.11 $114,703 - $185,315	1,780 New	1,780 $280,000
Q4 2018 Feb 12, 2019	SELL	$59.1 - $93.26 $105,198 - $166,002	-1,780 Closed	0 $0
Q2 2018 Aug 09, 2018	BUY	$99.64 - $127.59 $39,357 - $50,398	395 Added 28.52%	1,780 $279,000
Q4 2017 Feb 02, 2018	BUY	$81.25 - $130.7 $112,531 - $181,019	1,385	1,385 $247,000

152

63.7M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $25.5M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Cibc Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Cibc Asset Management Inc with notifications on news.